Objective: To describe sociodemographic characteristics and healthcare resource utilization (HRU) among Parkinson’s disease (PD) patients across US health insurance plans.

Background: PD affects nearly 1 million US patients with an estimated annual burden of $52 billion [1,2]. However, the impact of HRU across payers remains unknown.

Method: We conducted a retrospective cohort study in RWD Insights from 2014 to 2023 [3]. This data covers approximately 300 million lives across 50 US states with longitudinal, adjudicated closed claims from Medicare Fee-for-Service (FFS) and Medicare Part C, Medicaid FFS and managed Medicaid, other US governmental, and private commercial plans.

PD patients were identified by ≥1 PD diagnostic claim. Index date was first PD diagnosis, capturing prevalent and incident disease. Observation began all years prior to diagnosis till end of data availability or death.

Results: 951,342 PD patients (57.5% male) with median observation time of 7.8 years (IQR 5.0-9.4) were included. Median age at first PD claim was 75.5 years (IQR 68.6-78.3); 33.2% had reported deaths at median age 79.4 years (IQR 76.3-81.8). 89.9% of patients were White, 7.5% Black, 2.6% Asian, and 87.7% non-Hispanic, and were geographically dispersed (South 38.6%; Mid-West 22.3%; West 21.1%; Northeast 18.1%) with 96.5% in urban areas. 48.7% and 6.8% of patients had ≥1 encounter after PD diagnosis with a neurologist and neurosurgeon, respectively.

In 2022, 54.8% were covered by Medicare FFS, compared to Medicare Part C (29.0%), managed Medicaid (6.3%), commercial (5.8%), Medicaid FFS (2.1%), Dual-eligible (1.4%), and other US governmental (0.5%) plans. From 2014 to 2022, the percentage of patients on private commercial (11.2%; 5.8%) decreased while Medicare (78.4%; 83.8%) increased.

In 2022, median monthly all-cause adjudicated costs were $402 (IQR $96-1,675) for medical care and $84 for prescription drugs (IQR $13-391) per patient. Median combined monthly all-cause adjudicated cost was highest for Dual-eligibles ($1,346; IQR $212-7,232), followed by Medicare FFS ($642; IQR $146-2,436), managed Medicaid ($296; IQR $89-1,028), commercial ($233; IQR $67-791), Medicare Part C ($219; IQR $58-835), Medicaid FFS ($214; IQR $58-913), and other US governmental ($182; IQR $54-669) plans.

Conclusion: This study reveals the heterogeneity of PD medical care across different plans.

References: 1. Willis, A. W., Roberts, E., Beck, J. C., Fiske, B., Ross, W., Savica, R., Van Den Eeden, S. K., Tanner, C. M., Marras, C., & Parkinson’s Foundation P4 Group (2022). Incidence of Parkinson disease in North America. NPJ Parkinson’s disease, 8(1), 170. https://doi.org/10.1038/s41531-022-00410-y
2. Yang, W., Hamilton, J. L., Kopil, C., Beck, J. C., Tanner, C. M., Albin, R. L., Ray Dorsey, E., Dahodwala, N., Cintina, I., Hogan, P., & Thompson, T. (2020). Current and projected future economic burden of Parkinson’s disease in the U.S. NPJ Parkinson’s disease, 6, 15. https://doi.org/10.1038/s41531-020-0117-1
3. RWD Insights. Real-world data for real-world evidence: STATinMED [March 2024]. Available from: https://link.edgepilot.com/s/296ef35d/8nrWwShhDUiKlehZVrKdwA?u=https://statinmed.com/data/

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/characteristics-of-parkinsons-disease-and-associated-healthcare-resource-utilization-trends-in-a-us-all-payer-health-administrative-claims-database/